Mereo BioPharma Group
Tracked across 6 events · 288 articles · First seen Jan 28, 2026 · Last active Apr 06, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Business
Mereo BioPharma Group is facing a class action lawsuit due to allegedly misleading statements regarding its Phase 3 clinical trials for setrusumab. The failure of these trials led to a significant drop in its share price, causing substantial shareholder losses.
Feb 13, 2026 · 8 articles
Business
Mereo BioPharma Group is facing a shareholder class action lawsuit alleging false and misleading statements regarding its drug setrusumab. This could lead to significant financial penalties and reputational damage for the company.
Feb 05, 2026 · 7 articles
Regulatory
Mereo BioPharma Group is facing a class action lawsuit for allegedly disseminating false and misleading statements regarding its Phase 3 Orbit and COSMIC studies for setrusumab. This has caused investors to purchase its ADSs at artificially inflated prices, leading to potential damages.
Feb 05, 2026 · 45 articles
Business
Mereo BioPharma Group is facing a class action lawsuit due to alleged securities fraud and unlawful business practices. The company's ADR price significantly dropped following negative news regarding its Phase 3 studies for UX143 (setrusumab).
Jan 29, 2026 · 43 articles
Business
Mereo BioPharma Group is facing a federal securities class action lawsuit after two Phase 3 studies of setrusumab failed to meet their primary endpoints, leading to a significant drop in its stock price.
Feb 05, 2026 · 142 articles
+ 1 more events
View on Dashboard
NEWSDESK
Track Mereo BioPharma Group live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard